{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-065442","form_type":"8-K","ticker":null,"cik":"0001017491","company_name":"SEELOS THERAPEUTICS, INC.","filed_at":"2023-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.617050+00:00","generated_at":"2026-06-14T12:25:58.615392+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Seelos receives Nasdaq delisting notice; plans to appeal and may pursue reverse stock split","bullets":["Nasdaq notified Seelos on May 23, 2023 that it failed to regain compliance with $1.00 bid price rule.","Company is ineligible for a second 180-day compliance period because stockholders' equity is below $5M.","Seelos will request a hearing by May 30, 2023, staying suspension until the panel rules.","Hearing plan may include a reverse stock split to regain compliance with Rule 5550(a)(2).","If appeal is denied, common stock will be delisted from Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-065442","json":"https://secwatch.observer/filing/0001104659-23-065442.json","markdown":"https://secwatch.observer/filing/0001104659-23-065442.md","text":"https://secwatch.observer/filing/0001104659-23-065442.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1017491/000110465923065442/0001104659-23-065442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1017491/000110465923065442/tm2317105d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T12:25:58.615392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4898d97dcd2d5c54e1d0988a1db6dc62d51e940","claim":"SEELOS THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"May 23, 2023, the Listing Qualifications Staff of Nasdaq (the “Staff”) provided a notice to the Company (the “Nasdaq Notice”) that the Company has not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as the Company does not comply with the minimum $5,000,000 stockholder’s equity requirement for initial listing on the Nasdaq Capital Market. The Nasdaq Notice further indicated that, unless the Company requests a hearing on an appeal of this determination by the Staff before a Nasdaq Hearings Panel by no later than May 30, 2023, the Comp","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1017491/000110465923065442/0001104659-23-065442-index.htm","confidence":0.98,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}